Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab as adjunctive therapy in moderate to severe major depressive disorder
IRCT20090117001556N121Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of adalimumab in major depressive disorder (MDD), sponsored by Tehran University of Medical Sciences. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20090117001556N121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N121.